Need immediate assistance? Call 1-518-730-0559 (Us-Canada Toll Free) or Contact Us

 

Dementia Associated with Alzimer’s Disease Market – Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2018-2026

Table of Content

1. Preface
     1.1. Market Definition and Scope
     1.2. Market Segmentation
     1.3. Key Research Objectives
     1.4. Research Highlights

2. Assumptions and Research Methodology

3. Executive Summary: Global Dementia Associated with Alzheimer’s Disease Market 

4. Market Overview
     4.1. Introduction
            4.1.1. Drug Class Definition
            4.1.2. Industry Evolution / Developments
     4.2. Overview
     4.3. Market Dynamics
            4.3.1. Drivers
            4.3.2. Restraints
            4.3.3. Opportunities
     4.4. Global Dementia Associated with Alzheimer’s Disease Market Analysis and Forecast, 2016–2026
            4.4.1. Global Dementia Associated with Alzheimer’s Disease Market Value (US$ Mn) Projections
     4.5. Porter’s Five Force Analysis

5. Market Outlook
     5.1. Disease Prevalence & Incidence Rate Globally with Key Countries
     5.2. Pipeline Analysis

6. Global Dementia Associated with Alzheimer’s disease Market Analysis and Forecast, by Drug Class
     6.1. Introduction & Definition
     6.2. Key Findings / Developments
     6.3. Global Dementia Associated with Alzheimer’s disease Market Value Forecast, by Drug Class, 2016–2026
            6.3.1. Cholinergic/ Cholinesterase (ChE) Inhibitors 
                     6.3.1.1. Donepezil 
                     6.3.1.2. Galantamine
                     6.3.1.3. Rivastigmine
            6.3.2. Memantine 
            6.3.3. Combined Drug (Memantine & Donepezil) and Others
     6.4. Global Dementia Associated with Alzheimer’s disease Market Attractiveness, by Drug Class

7. Global Dementia Associated with Alzheimer’s disease Market Analysis and Forecast, by Distribution Channel 
     7.1. Introduction & Definition
     7.2. Key Findings / Developments
     7.3. Global Dementia Associated with Alzheimer’s Disease Market Value Forecast, by Distribution Channel, 2016–2026
            7.3.1. Hospital Pharmacies
            7.3.2. Retail 
            7.3.3. Online Sales 
     7.4. Global Dementia Associated with Alzheimer’s Disease Market Attractiveness, by Distribution Channel 

8. Global Dementia Associated with Alzheimer’s Disease Market Analysis and Forecast, by Region
     8.1. Key Findings
     8.2. Global Dementia Associated with Alzheimer’s Disease Market Value Forecast, by Region
            8.2.1. North America 
            8.2.2. Europe 
            8.2.3. Asia Pacific 
            8.2.4. Latin America 
            8.2.5. Middle East & Africa 
     8.3. Global Dementia Associated with Alzheimer’s Disease Market Attractiveness, by Country/Region

9. North America Dementia Associated with Alzheimer’s Disease Market Analysis and Forecast
     9.1. Introduction
            9.1.1. Key Findings
     9.2. North America Dementia Associated with Alzheimer’s Disease Market Value Forecast, by Drug Class, 2016–2026
            9.2.1. Cholinergic/ Cholinesterase (ChE) Inhibitors 
                     9.2.1.1. Donepezil 
                     9.2.1.2. Galantamine
                     9.2.1.3. Rivastigmine
            9.2.2. Memantine 
            9.2.3. Combined Drug (Memantine & Donepezil) and Others
     9.3. North America Dementia Associated with Alzheimer’s Disease Market Value Forecast, by Distribution Channel, 2016–2026
            9.3.1. Hospital Pharmacies
            9.3.2. Retail 
            9.3.3. Online Sales 
     9.4. North America Dementia Associated with Alzheimer’s Disease Market Value Forecast, by Country, 2016–2026
            9.4.1. U.S.
            9.4.2. Canada 
     9.5. North America Dementia Associated with Alzheimer’s Disease Market Attractiveness Analysis 
            9.5.1. By Drug Class
            9.5.2. By Distribution Channel 
            9.5.3. By Country

10. Europe Dementia Associated with Alzheimer’s Disease Market Analysis and Forecast
     10.1. Introduction
            10.1.1. Key Findings
     10.2. Europe Dementia Associated with Alzheimer’s Disease Market Value Forecast, by Drug Class, 2016–2026
            10.2.1. Cholinergic/ Cholinesterase (ChE) Inhibitors 
                     10.2.1.1. Donepezil 
                     10.2.1.2. Galantamine
                     10.2.1.3. Rivastigmine
            10.2.2. Memantine 
            10.2.3. Combined Drug (Memantine & Donepezil) and Others
     10.3. Europe Dementia Associated with Alzheimer’s Disease Market Value Forecast, by Distribution Channel, 2016–2026
            10.3.1. Hospital Pharmacies
            10.3.2. Retail 
            10.3.3. Online Sales 
     10.4. Europe Dementia Associated with Alzheimer’s Disease Market Value Forecast, by Country/Sub-region, 2016–2026
            10.4.1. Germany
            10.4.2. France
            10.4.3. U.K.
            10.4.4. Italy
            10.4.5. Spain
            10.4.6. Rest of Europe
     10.5. Europe Dementia Associated with Alzheimer’s Disease Market Attractiveness Analysis 
            10.5.1. By Drug Class
            10.5.2. By Distribution Channel 
            10.5.3. By Country/Sub-region

11. Asia Pacific Dementia Associated with Alzheimer’s Disease Market Analysis and Forecast
     11.1. Introduction
            11.1.1. Key Findings
     11.2. Asia Pacific Dementia Associated with Alzheimer’s Disease Market Value Forecast, by Drug Class, 2016–2026
            11.2.1. Cholinergic/ Cholinesterase (ChE) Inhibitors 
                     11.2.1.1. Donepezil 
                     11.2.1.2. Galantamine
                     11.2.1.3. Rivastigmine
            11.2.2. Memantine 
            11.2.3. Combined Drug (Memantine & Donepezil) and Others
     11.3. Asia Pacific Dementia Associated with Alzheimer’s Disease Market Value Forecast, by Distribution Channel, 2016–2026
            11.3.1. Hospital Pharmacies
            11.3.2. Retail 
            11.3.3. Online Sales 
     11.4. Asia Pacific Dementia Associated with Alzheimer’s Disease Market Value Forecast, by Country/Sub-region, 2016–2026
            11.4.1. Japan
            11.4.2. China
            11.4.3. India
            11.4.4. Australia & New Zealand
            11.4.5. Rest of Asia Pacific
     11.5. Asia Pacific Dementia Associated with Alzheimer’s Disease Market Attractiveness Analysis 
            11.5.1. By Drug Class
            11.5.2. By Distribution Channel 
            11.5.3. By Country/Sub-region

12. Latin America Dementia Associated with Alzheimer’s Disease Market Analysis and Forecast
     12.1. Introduction
            12.1.1. Key Findings
     12.2. Latin America Dementia Associated with Alzheimer’s Disease Market Value Forecast, by Drug Class, 2016–2026
            12.2.1. Cholinergic/ Cholinesterase (ChE) Inhibitors 
                     12.2.1.1. Donepezil 
                     12.2.1.2. Galantamine
                     12.2.1.3. Rivastigmine
            12.2.2. Memantine 
            12.2.3. Combined Drug (Memantine &Donepezil) and Others
     12.3. Latin America Dementia Associated with Alzheimer’s Disease Market Value Forecast, by Distribution Channel, 2016–2026
            12.3.1. Hospital Pharmacies
            12.3.2. Retail 
            12.3.3. Online Sales 
     12.4. Latin America Dementia Associated with Alzheimer’s Disease Market Value Forecast, by Country/Sub-region, 2016–2026
            12.4.1. Brazil
            12.4.2. Mexico
            12.4.3. Rest of Latin America
     12.5. Latin America Dementia Associated with Alzheimer’s Disease Market Attractiveness Analysis 
            12.5.1. By Drug Class
            12.5.2. By Distribution Channel 
            12.5.3. By Country/Sub-region

13. Middle East & Africa Dementia Associated with Alzheimer’s Disease Market Analysis and Forecast
     13.1. Introduction
            13.1.1. Key Findings
     13.2. Middle East & Africa Dementia Associated with Alzheimer’s Disease Market Value Forecast, by Drug Class, 2016–2026
            13.2.1. Cholinergic/ Cholinesterase (ChE) Inhibitors 
                     13.2.1.1. Donepezil 
                     13.2.1.2. Galantamine
                     13.2.1.3. Rivastigmine
            13.2.2. Memantine 
            13.2.3. Combined Drug (Memantine & Donepezil) and Others
     13.3. Middle East & Africa Dementia Associated with Alzheimer’s Disease Market Value Forecast, by Distribution Channel, 2016–2026
            13.3.1. Hospital Pharmacies
            13.3.2. Retail 
            13.3.3. Online Sales 
     13.4. Middle East & Africa Dementia Associated with Alzheimer’s Disease Market Value Forecast, by Country/Sub-region, 2016–2026
            13.4.1. GCC Countries
            13.4.2. Israel
            13.4.3. South Africa
            13.4.4. Rest of MEA
     13.5. Middle East & Africa Dementia Associated with Alzheimer’s Disease Market Attractiveness Analysis 
            13.5.1. By Drug Class
            13.5.2. By Distribution Channel 
            13.5.3. By Country/Sub-region

14. Competition Landscape
     14.1. Market Player – Competition Matrix (By Tier and Size of companies)
     14.2. Market Share Analysis by Company (2016)
     14.3. Market Footprint Analysis
            14.3.1. By Region
            14.3.2. By Drug Class Type
     14.4. Competitive Business Strategies
     14.5. Company Profiles
            14.5.1. Merz Pharma GmbH & Co. KGaA 
                     14.5.1.1. Company Overview (HQ, Business Segments, Employee Strength)
                     14.5.1.2. Product Portfolio
                     14.5.1.3. SWOT Analysis
                     14.5.1.4. Financial Overview
                     14.5.1.5. Strategic Overview
            14.5.2. Novartis AG  
                     14.5.2.1. Company Overview (HQ, Business Segments, Employee Strength)
                     14.5.2.2. Product Portfolio
                     14.5.2.3. SWOT Analysis
                     14.5.2.4. Financial Overview
                     14.5.2.5. Strategic Overview
            14.5.3. Allergan plc.
                     14.5.3.1. Company Overview (HQ, Business Segments, Employee Strength)
                     14.5.3.2. Product Portfolio
                     14.5.3.3. SWOT Analysis
                     14.5.3.4. Financial Overview
                     14.5.3.5. Strategic Overview
            14.5.4. Pfizer, Inc.  
                     14.5.4.1. Company Overview (HQ, Business Segments, Employee Strength)
                     14.5.4.2. Product Portfolio
                     14.5.4.3. SWOT Analysis
                     14.5.4.4. Financial Overview
                     14.5.4.5. Strategic Overview
            14.5.5. Daiichi Sankyo Company, Limited  
                     14.5.5.1. Company Overview (HQ, Business Segments, Employee Strength)
                     14.5.5.2. Product Portfolio
                     14.5.5.3. SWOT Analysis
                     14.5.5.4. Financial Overview
                     14.5.5.5. Strategic Overview
            14.5.6. Ono Pharmaceutical Co., Ltd. 
                     14.5.6.1. Company Overview (HQ, Business Segments, Employee Strength)
                     14.5.6.2. Product Portfolio
                     14.5.6.3. SWOT Analysis
                     14.5.6.4. Financial Overview
                     14.5.6.5. Strategic Overview
            14.5.7. Johnson & Johnson Services, Inc. 
                     14.5.7.1. Company Overview (HQ, Business Segments, Employee Strength)
                     14.5.7.2. Product Portfolio
                     14.5.7.3. SWOT Analysis
                     14.5.7.4. Financial Overview
                     14.5.7.5. Strategic Overview
            14.5.8. Eisai Co., Ltd. 
                     14.5.8.1. Company Overview (HQ, Business Segments, Employee Strength)
                     14.5.8.2. Product Portfolio
                     14.5.8.3. SWOT Analysis
                     14.5.8.4. Financial Overview
                     14.5.8.5. Strategic Overview
            14.5.9. H. Lundbeck A/S 
                     14.5.9.1. Company Overview (HQ, Business Segments, Employee Strength)
                     14.5.9.2. Product Portfolio
                     14.5.9.3. SWOT Analysis
                     14.5.9.4. Financial Overview
                     14.5.9.5. Strategic Overview
            14.5.10. F. Hoffmann-La Roche Ltd.  
                     14.5.10.1. Company Overview (HQ, Business Segments, Employee Strength)
                     14.5.10.2. Product Portfolio
                     14.5.10.3. SWOT Analysis
                     14.5.10.4. Financial Overview
                     14.5.10.5. Strategic Overview

Custom Market Research Services

MRRSE offers custom market research services that help clients to get information on their business scenario required where syndicated solutions are not enough.

Get A Free Custom Research Quote